An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy.

中文翻译：

---

PARP抑制-胰腺癌的机会

存在迫切的临床需求，以通过生物标记物驱动的治疗策略来改善胰腺癌患者的生存。这样的方法包括以聚铂（ADP-核糖）聚合酶抑制剂为靶标，将具有种系BRCA突变的转移性胰腺癌作为靶向疗法，进行铂类化学疗法后的维持治疗。